Skip to content

Battle Of Two Orphan Drugs: Aegerion Pharmaceuticals’ Lomitapide Verses Genzyme’s Mipomersen: SeekingAlpha.com Perspective

October 16, 2012

         Two orphan drugs, Aegerion Pharmaceuticals’ Lomitapide and Genzyme and Isis Pharmaceuticals’ Mipomersen, are being reviewed October 17 and 18, 2012, by the same FDA Advisory Committee for the same indication, Homozygous Familial Hypercholesterolemia (HoFH).  

          Lomitapide has a December 29, 2012, PDUFA date and Mipromersen has a January 29, 2013, PDUFA date.           

References 

SeekingAlpha.com October 15, 2012 Article titled,”Aegerion Vs. Isis: Which 1 is the Buy ?”  

SeekingAlpha.com July 2, 2012 Article titled,”Physician Survey Results On Lomitapide and Mipomersen Support Our Thesis”  

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: